Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Autolus Therapeutics plc - American Depositary Shares (NQ:AUTL)

2.240 -0.050 (-2.18%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Autolus Therapeutics plc - American Depositary Shares

< Previous 1 2 3 4 Next >
News headline image
Autolus (AUTL) Q2 2026 Earnings Call Transcript ↗
Revenue surged 119% year-over-year as gross margins turned positive for the first time. 
Via The Motley Fool
Topics Earnings
News headline image
Autolus Therapeutics Q2 Earnings Call Highlights ↗
Autolus Therapeutics (NASDAQ:AUTL) reported second-quarter 2026 net product revenue of $45.7 million from sales of AUCATZYL, up from $26.2 million in the first quarter and $20.9 million a year earlier,... 
Via MarketBeat
Topics Earnings
Top stock movements in today's session. ↗
Via Chartmill
Autolus Therapeutics (NASDAQ:AUTL) Posts Inline Q1 Results with First Positive Gross Margin, but Full-Year Guidance Slightly Below Consensus ↗
Via Chartmill
News headline image
Earnings Scheduled For November 12, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Autolus Therapeutics Through 5 Analysts ↗
 
Via Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
Autolus (AUTL) Q1 2026 Earnings Transcript ↗
Autolus (AUTL) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Autolus Therapeutics Q1 Earnings Call Highlights ↗
Autolus Therapeutics (NASDAQ:AUTL) reported higher first-quarter 2026 product revenue and said its commercial launch of AUCATZYL is gaining traction in the U.S. and U.K., while reiterating full-year... 
Via MarketBeat
Topics Earnings
News headline image
AUTL Stock Soars Pre-market On Positive Recommendation For Cell Therapy Targeting Cancer In UK ↗
NICE has recommended that Aucatzyl be used as a treatment option for adult patients aged 26 years or older with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, the company said. 
Via Stocktwits
News headline image
A Look at Autolus Therapeutics's Upcoming Earnings Report ↗
 
Via Benzinga
News headline image
FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers ↗
FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment. 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Autolus Therapeutics ↗
 
Via Benzinga
News headline image
Autolus Therapeutics Gets Favorable Recommendation For Approval Of Cancer Therapy In EU: Retail Sentiment Brightens ↗
CHMP has recommended that the European Commission approve the therapy for treating adult patients over the age of 26 with relapsed or refractory B-cell precursor acute Lymphoblastic Leukemia. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Earnings Scheduled For August 12, 2025 ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 20, 2025 ↗
 
Via Benzinga
News headline image
This InterContinental Hotels Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday ↗
 
Via Benzinga
News headline image
Nvidia To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
Why Revelation Biosciences Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
AUTL Stock Earnings: Autolus Therapeutics Misses EPS for Q2 2024 ↗
AUTL stock results show that Autolus Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget ↗
Since wealth without health is utterly meaningless, investors may have some confidence with these biotech stocks to buy. 
Via InvestorPlace
News headline image
Crude Oil Gains 1%; GameStop Shares Plunge ↗
 
Via Benzinga
News headline image
Why Cracker Barrel Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
 
Via Benzinga
News headline image
AUTL Stock Earnings: Autolus Therapeutics Misses EPS, Misses Revenue for Q1 2024 ↗
AUTL stock results show that Autolus Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Despegar.com Posts Strong Sales, Joins Reddit, Robinhood And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.